Lanthanum carbonate 1g chewable tablets
Requires a prescription from a doctor or prescriber
Lanthanum carbonate is a phosphate binder marketed under the trade name <em>Fosrenol</em> by Shire Pharmaceuticals.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Lanthanum carbonate on the MHRA register
Fosrenol 1000mg chewable tablets
Lanthanum carbonate 1g chewable tablets
Lanthanum carbonate 1g chewable tablets
Lanthanum carbonate 1g chewable tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
2.25 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 18 · Randomised trials: 14 · 2001–2025
Showing the 50 most relevant studies, sorted by most relevant.
A. Hutchison, Bart Maes, Johan Vanwalleghem, et al.
Nephron Clinical Practice, 2005
- Calcium
- Calcium Carbonate
- Lanthanum
Chenglong Zhang, Ji Wen, Zi Li, et al.
BMC Nephrology, 2013
- China
- Renal Dialysis
- Lanthanum
Hui Fang, Chunyan Chen
American journal of translational research, 2024
Hui Fang, Chunyan Chen
2024
Nigel D. Toussaint, Kenneth K. Lau, Kevan R. Polkinghorne, et al.
Nephrology, 2010
- Renal Dialysis
- Aortic Diseases
- Aortography
Jan Kampmann, Nina Pirschel Hansen, Anders Nikolai Ørsted Schultz, et al.
Diagnostics, 2022
Junlan Yang, Xiaoliang Zhang, Lina Wang
Clinical Nephrology, 2022
- Calcium Carbonate
- Fibroblast Growth Factor-23
- Lanthanum
Xia Chen, Min Xiu, Juanjuan Xing, et al.
Cellular Physiology and Biochemistry, 2017
- Cell Survival
- Cells, Cultured
- Histones
Junlan Yang, Xiao liang Zhang, Lina Wang
Nephrology Dialysis Transplantation, 2021
F. Wang, Xiangxue Lu, Jingli Zhang, et al.
Kidney and Blood Pressure Research, 2018
- Cardiovascular Diseases
- Lanthanum
- Calcium
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
53 hours
Mechanism
Lanthanum carbonate is a phosphate binder that reduces absorption of phosphate b…
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1.0 ng/mL
Half-life
53 hours
[L50733]
Protein binding
99%
[L50733]
Metabolism
[L50733]
Elimination
99%
Clearance
120 μg
[L50733]…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L50733]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 89 interactions
In comparison to [sevelemer], another common phosphate binder, lanthanum carbonate is more efficacious in lowering serum phosphate concentrations and effectively managing hyperphosphatemia.[A263803]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L50733]
The timing of food intake relative to lanthanum administration (during and 30 minutes after food intake) has a negligible effect on the systemic level of lanthanum.
[L50733]
[L50733]
[L50733]
[L50733]
[L50733]
Biliary excretion is the predominant route of elimination for circulating lanthanum in rats.
[L50733]
[L50733]
ATC V03AE03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Lanthanum carbonate
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q421317), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.